NYSE:BSX • US1011371077
The current stock price of BSX is 74.73 USD. In the past month the price decreased by -16.99%. In the past year, price decreased by -29.57%.
ChartMill assigns a fundamental rating of 6 / 10 to BSX. BSX scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 3.05. The EPS increased by 21.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.42% | ||
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| Debt/Equity | 0.48 |
40 analysts have analysed BSX and the average price target is 125.5 USD. This implies a price increase of 67.94% is expected in the next year compared to the current price of 74.73.
For the next year, analysts expect an EPS growth of 14.83% and a revenue growth 11.42% for BSX
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.62 | 193.832B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.53 | 169.664B | ||
| SYK | STRYKER CORP | 24.21 | 139.908B | ||
| BDX | BECTON DICKINSON AND CO | 11.16 | 50.66B | ||
| IDXX | IDEXX LABORATORIES INC | 42.48 | 49.283B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.52 | 44.358B | ||
| RMD | RESMED INC | 20.57 | 35.869B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 35.845B | ||
| DXCM | DEXCOM INC | 27.73 | 25.383B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752 US
CEO: Michael F. Mahoney
Employees: 53000
Phone: 13026365400
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
The current stock price of BSX is 74.73 USD. The price increased by 0.82% in the last trading session.
BSX does not pay a dividend.
BSX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
BOSTON SCIENTIFIC CORP (BSX) currently has 53000 employees.
The outstanding short interest for BOSTON SCIENTIFIC CORP (BSX) is 1.59% of its float.